InsiderTrades

Form 4 for SLSN SOLESENCE, INC.

Accepted 2021-11-24 00:00:00 ET · period of report 2021-11-22 · accession 0001209191-21-066811 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2021-11-24 2021-11-22+ SLSN Cureton Kevin COO M - OptEx $0.4541 +36.4K 50.4K +260% +$16.5K
DM 2021-11-24 2021-11-22+ SLSN Cureton Kevin COO S - Sale+OE $3.82 -36.4K 25.6K -59% -$139.0K
DM 2021-11-24 2021-11-22+ SLSN Cureton Kevin COO M - OptEx $0.4541 -36.4K 0 -100% -$16.5K

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2021-11-22 M A 11,668 $0.42 37,318 D — —
2 Common Common Stock 2021-11-22 S D 11,668 $3.92 25,650 D — —
3 Common Common Stock 2021-11-24 M A 12,332 $0.42 37,982 D — —
4 Common Common Stock 2021-11-24 M A 12,393 $0.52 50,375 D — —
5 Common Common Stock 2021-11-24 S D 24,725 $3.77 25,650 D — —
6 Derivative Common Stock (right to purchase) 2021-11-24 M D 12,393 $0.52 62,607 D $0.52 · 2015-02-13 to 2024-02-13 75,000 Common Stock (F3) Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.
7 Derivative Common Stock (right to purchase) 2021-11-24 M D 12,332 $0.42 24,000 D $0.42 · 2014-02-14 to 2023-02-14 36,332 Common Stock (F2) This line item represents the 2nd sale, of 12,332 shares of a total initial grant of 48,000 shares, leaving a balance of 24,000 shares remaining relating to this grant. (F3) Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.
8 Derivative Common Stock (right to purchase) 2021-11-22 M D 11,668 $0.42 0 D $0.42 · 2014-02-14 to 2023-02-14 11,668 Common Stock (F1) This line item represents the 1st sale of 11,668 shares of a total grant of 48,000 shares, leaving a balance of 36,332 shares remaining relating to this grant.